TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20367790
Drug: CR-rhIFN-α(2b) 160
Normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR-rhIFN-α(2b) 160 μg every 2 weeks for 12 weeks with ribavirin
Study: 20367790
Drug: CR-rhIFN-α(2b) 320
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR-rhIFN-α(2b) 320 μg every 2 weeks for 12 weeks with ribavirin
Study: 20367790
Drug: CR-rhIFN-α(2b) 480
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR-rhIFN-α(2b) 480 μg every 2 weeks for 12 weeks with ribavirin
Study: 20367790
Drug: CR-rhIFN-α(2b) 640
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR-rhIFN-α(2b) 640 μg every 2 weeks for 12 weeks with ribavirin
Study: 12877758
Drug: β1-selective β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β1-selective β-blockers (nebivolol)
Study: 1313078
Drug: L-threonine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine (2 g daily)
Study: 31500139
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training with carbohydrate administration before each session
Study: 31500139
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training without carbohydrate administration
Study: 31500139
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training with carbohydrate administration
Study: 28294318
Drug: Impact of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of Killing (IOK) treatment (N = 17)
Study: 25728731
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists (MRAs) therapy
Study: 25728731
Drug: No MRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No MRA therapy
Study: 24026142
Drug: hydrochlorothiazide (diuretic)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (diuretic)
Study: 22174074
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of standardized extract from Ageratina pichinchensis
Study: 16159535
Drug: 1-month tapering
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month tapering of antiepileptic drug
Study: 16159535
Drug: 6-month tapering
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month tapering of antiepileptic drug
Study: 1963701
Drug: CDDP 200
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 200 mg/m2 administered in arm A (100 mg/m2 on Day 1 and Day 8)
Study: 1963701
Drug: CDDP 200
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 200 mg/m2 administered in arm B (40 mg/m2 per day during 5 consecutive days)
Study: 24330656
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 21 mg transdermal nicotine patches for 8-12 weeks and withdrawal-oriented behavioural support for 7 sessions
Study: 11330759
Drug: Second-line drugs
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line drugs treatment for six months
Study: 19140498
Drug: Tibolone therapy
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone therapy (2.5 mg daily for 1 year)
Study: 8571194
Drug: Rapid protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid protamine administration (1.5 mg/kg over 3 minutes)
Study: 8571194
Drug: Slow protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow protamine administration (1.5 mg/kg over 15 minutes)
Study: 1929241
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (0.25 mg/kg)
Study: 1929241
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (1.5 mg/kg)
Study: 31797473
Drug: Crocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (30 mg/day)
Study: 31797473
Drug: Saffron aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron aqueous extract (SAE) (30 mg/day)
Study: 31586644
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + aPDT (photodynamic therapy)
Study: 29478239
Drug: PF-06669571 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06669571 (1 mg to 3 mg over 7 days)
Study: 23113833
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Study: 23113833
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Study: 23113833
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin daily plus placebo once every 2 weeks
Study: 23113833
Drug: SAR236553 (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR236553 (combined with atorvastatin)
Study: 23113833
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin plus placebo
Study: 18845960
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine or perinatal zidovudine treatment
Study: 15911239
Drug: Glutamine and
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine and asparagine concentrations at Day 14 in Group L
Study: 15911239
Drug: Glutamic acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamic acid amounts at Day 14 in Group L
Study: 12621013
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion at 0.40 IDU/kg over 20 min
Study: 12621013
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion at 0.40 IDU/kg
Study: 30640988
Drug: Sub-hyperthermia foot
Normalized name: Fungi-Nail Toe and Foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM), 30 min each time, once per day for 3 months
Study: 30640988
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of Western medicine (WM)
Study: 30640988
Drug: Sub-hyperthermia foot
Normalized name: Fungi-Nail Toe and Foot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM)
Study: 26179672
Drug: Methylprednisolone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (80 mg)
Study: 22532661
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration oxygen (8 L/min via medium concentration mask)
Study: 15705007
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg b.i.d.)
Study: 14625517
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (10 g/day for 4 days)
Study: 14625517
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (25 g/day for 4 days)
Study: 14625517
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (35 g/day for 4 days)
Study: 1892004
Drug: Cefpirome 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 0.5 g b.i.d. (1 g group)
Study: 1892004
Drug: Cefpirome 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1.0 g b.i.d. (2 g group)
Study: 1892004
Drug: Ceftazidime 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1.0 g b.i.d. (CAZ group)
Study: 6436732
Drug: Carbohydrate intake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate intake (rapidly or slowly absorbed sugars, given by mouth or IV injection)
Study: 27006655
Drug: 2800 IU
Normalized name: Alendronate Sodium/Cholecalciferol 70 MG-2800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2800 IU vitamin D3 daily for eight weeks
Study: 20528599
Drug: Long-acting beta-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta-agonists (LABAs)
Study: 18623040
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI (repeated dose)
Study: 2023417
Drug: Methotrexate 50
Normalized name: methotrexate 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 50 mg/m2
Study: 9423749
Drug: Methotrexate 60
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 60 mg/m2
Study: 9423749
Drug: Methotrexate 50
Normalized name: methotrexate 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 50 mg/m2 and 60 mg/m2
Study: 8255928
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% escin gel
Study: 3307307
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation 2,000 mg daily
Study: 31152567
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using toluidine blue (10 mg/mL; 3 min) and a 635-nm laser (750 mW; 10 s/implant side; minimum of 60 mW/cm2)
Study: 11996212
Drug: Metadate CD
Normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metadate CD (20 mg capsule)
Study: 11996212
Drug: Concerta (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta (18 mg tablet)
Study: 11996212
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 20 mg capsules
Study: 11996212
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 20 mg capsules
Study: 9476972
Drug: Oral delta9-tetrahydrocannabinol
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral delta9-tetrahydrocannabinol (delta9-THC) 7.5 mg
Study: 9476972
Drug: Oral delta9-tetrahydrocannabinol
Normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral delta9-tetrahydrocannabinol (delta9-THC) 15 mg
Study: 7666121
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg i.v. every 24 hours
Study: 7666121
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg per os every 24 hours
Study: 7666121
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg per os every 12 hours
Study: 2698804
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS) 125 mg/day intravenous for 8 weeks
Study: 28100606
Drug: Predictive Low-Glucose
Normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive Low-Glucose Insulin Suspension (PLGS)
Study: 25739904
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intraventricular TPA every 12 h (five doses)
Study: 25739904
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 12 h (five doses)
Study: 24517060
Drug: Yishen Qingli
Normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Qingli Granule (YQG) combined with low-dose Tripterygium Wilfordii multiglycoside Tablet (TWT)
Study: 16280561
Drug: Controlling for
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlling for prior history of depression, increased life stress, and current psychoactive medication
Study: 11573100
Drug: Bismuth subcitrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subcitrate 120 mg plus metronidazole 250 mg plus tetracycline 250 mg qid plus omeprazole 20 mg bid for 7 days (OBMT)
Study: 9400034
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg/day for 7 days, then 200 mg/day until discharge)
Study: 7960359
Drug: Levamisole +
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole + topical 0.1% fluocinolone acetonide
Study: 7960359
Drug: Levamisole +
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole + topical 0.05% clobetasol propionate
Study: 3654034
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide 50 mg, p.o. 3 times per day for 1 week
Study: 3654034
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (exact dosage not specified)
Study: 31724349
Drug: Nifedipine (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (control group treatment).
Study: 26416334
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy in consecutive sessions
Study: 22101876
Drug: Diet enriched
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet enriched with carp meat (200 g twice weekly for 4 weeks)
Study: 19747918
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a (90 microg/week) maintenance therapy
Study: 9631802
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) 150 mg/kg bolus, followed by a continuous infusion of 50 mg/kg over 4 hours (n=12)
Study: 25948208
Drug: Compound Zaofan
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Zaofan pill combined with cyclosporine and androgen
Study: 12620132
Drug: Centrally acting
Normalized name: Other centrally acting agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally acting antihypertensive drugs and beta‐adrenergic blockers
Study: 12620132
Drug: Calcium‐channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐channel blocker verapamil
Study: 8648358
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with 1.2 Gy twice daily to a total dose of 69.6 Gy (n = 66)
Study: 8648358
Drug: HFX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX RT with CHT consisting of 50 mg of carboplatin and 50 mg of etoposide given on each RT day (n = 65)
Study: 1626664
Drug: Subarachnoid hyperbaric
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 50 micrograms of fentanyl (group A)
Study: 1626664
Drug: Subarachnoid hyperbaric
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 25 micrograms of fentanyl (group B)
Study: 1626664
Drug: Subarachnoid hyperbaric
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 12.5 micrograms of fentanyl (group C)
Study: 1626664
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of saline (group D)
Study: 28382618
Drug: Bortezomib 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.6 mg/m2 intravenously on days 1, 8, 15, and 22 for four 35-day cycles
Study: 23647281
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (ABBT and AR)
Study: 16482646
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg administered twice weekly
Study: 16482646
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg administered twice weekly
Study: 8127928
Drug: Moclobemide (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (81 patients, 100-300 mg/day)
Study: 8127928
Drug: Tranylcypromine (79
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (79 patients, 10-30 mg/day)
Study: 3038552
Drug: Blood from
Normalized name: Blood from surgical drain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood from donors without detectable CMV antibodies (CMV seronegative blood)
Study: 27303062
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy intervention
Study: 31362784
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg per day)
Study: 28587620
Drug: Methadone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (40 mg per day)
Study: 21169634
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at pericardium 6 bilaterally, depth of approximately 0.7 cm, median duration of 21 min during anaesthesia, followed by acupressure wristbands for 24 h and standard treatment.
Study: 16948927
Drug: Risperidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1 mg/day for 6 months)
Study: 14503797
Drug: Leuprorelin (11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin (11.25 mg s.c. every 3 months for 2 years)
Study: 14503797
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (6 cycles)
Study: 11154141
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily (HRT group)
Study: 30172995
Drug: Phospholipid intake
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid intake (2.7 g/d for 6 weeks)
Study: 23430390
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZR) at a starting dose of 12 mg/kg/day
Study: 23430390
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a starting dose of 2 g/day
Study: 20690864
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg oral conjugated estrogens for 30 days
Study: 16916335
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus structured education on the use of a written self-management plan and patient-initiated short courses of antibiotics and oral corticosteroids
Study: 15315625
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM and normal saline IV
Study: 15315625
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg IM and tenoxicam 40 mg IV
Study: 15315625
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CPM) 20 mg IM and normal saline IV
Study: 17712576
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (non-operated group)
Study: 2871788
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Study: 2871788
Drug: 4-month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Study: 2871788
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 6-month series
Study: 2871788
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 4-month series
Study: 15822041
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium, 18 oz daily for 6 months
Study: 15822041
Drug: Carbohydrate-based placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-based placebo formula, 18 oz daily for 6 months
Study: 8520812
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with naltrexone
Study: 1996763
Drug: Procaine 10
Normalized name: procaine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine 10 mg
Study: 1996763
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 0.5 ml (Control)
Study: 19179917
Drug: Resorbable poly-L-lactide-co-D,L-lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resorbable poly-L-lactide-co-D,L-lactide (PLDLLA) cage
Study: 17690198
Drug: beta-alanine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-alanine (4.8 g/day)